Holen Sie sich die Stockscreener-App
164.24
3.95%
6.24
Handel nachbörslich:
164.24
Schlusskurs vom Vortag:
$158.00
Offen:
$154.09
24-Stunden-Volumen:
2.06M
Relative Volume:
2.34
Marktkapitalisierung:
$8.08B
Einnahmen:
$4.02B
Nettoeinkommen (Verlust:
$-79.62M
KGV:
-105.61
EPS:
-1.5551
Netto-Cashflow:
$543.67M
1W Leistung:
+3.46%
1M Leistung:
-25.24%
6M Leistung:
+3.63%
1J Leistung:
-0.46%
1-Tages-Spanne:
$151.31
$165.12
1-Wochen-Bereich:
$146.33
$165.12
52-Wochen-Spanne:
$91.86
$228.88
Charles River Laboratories International Inc Stock (CRL) Company Profile
Firmenname
Charles River Laboratories International Inc
Sektor
Branche
Telefon
781-222-6000
Adresse
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
164.24 | 7.78B | 4.02B | -79.62M | 543.67M | -1.5551 |
|
TMO
Thermo Fisher Scientific Inc
|
515.12 | 192.95B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
211.25 | 147.43B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
630.73 | 50.70B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
126.34 | 35.90B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
328.66 | 32.13B | 3.17B | 642.63M | 539.81M | 10.77 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-11-17 | Hochstufung | Argus | Hold → Buy |
| 2025-11-06 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-10-06 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-09-09 | Hochstufung | Jefferies | Hold → Buy |
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-05-23 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-05-08 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-03-21 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-03 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | Herabstufung | UBS | Buy → Neutral |
| 2024-11-18 | Herabstufung | CLSA | Hold → Underperform |
| 2024-11-07 | Hochstufung | CLSA | Underperform → Hold |
| 2024-10-23 | Eingeleitet | CLSA | Underperform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Sell |
| 2024-10-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-01 | Herabstufung | Citigroup | Neutral → Sell |
| 2024-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Herabstufung | Argus | Buy → Hold |
| 2024-06-07 | Eingeleitet | Mizuho | Neutral |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-02-15 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-09-13 | Eingeleitet | TD Cowen | Market Perform |
| 2023-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-02-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-12 | Herabstufung | Jefferies | Buy → Hold |
| 2022-09-30 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-04 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Eingeleitet | Guggenheim | Neutral |
| 2022-04-25 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-07 | Eingeleitet | Stephens | Overweight |
| 2022-02-17 | Bestätigt | BofA Securities | Buy |
| 2022-02-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-17 | Bestätigt | Deutsche Bank | Buy |
| 2022-02-17 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-17 | Bestätigt | UBS | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-07-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-05-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-04-21 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-02-18 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Hochstufung | Goldman | Neutral → Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-18 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-04-30 | Fortgesetzt | Evercore ISI | Outperform |
| 2018-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2018-10-09 | Eingeleitet | UBS | Neutral |
| 2018-08-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten
Charles River Laboratories NYSE CRL Quarterly Profit Streak Tests Bearish Profitability Narrative - simplywall.st
Assessing Charles River Laboratories (CRL) Valuation After Recent Share Price Weakness - Yahoo Finance
Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2025 Earnings Call Transcript - Insider Monkey
CenterBook Partners LP Raises Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Strategic Review at Charles River Laboratories Raises Deal Uncertainty, Execution Risks, and Shareholder Value Concerns - TipRanks
Decoding Charles River Laboratories International Inc (CRL): A S - GuruFocus
Charles River Laboratories (CRL) Exceeds Q4 Revenue Expectations with Strategic Growth - GuruFocus
Charles River (CRL) Anticipates Steady Revenue Growth through FY - GuruFocus
The Bull Case For Charles River Laboratories (CRL) Could Change Following 2025 Losses And New Leadership Appointments - Yahoo Finance
Charles River Laboratories (CRL) Appoints New Chief Financial Of - GuruFocus
Glenn Coleman and Kerry Dailey to join Charles River Labs leadership By Investing.com - Investing.com South Africa
Why Charles River Labs Stock Is Sliding Today - TipRanks
Charles River Labs Eyes Margin Gains Amid Flat Growth - TipRanks
Charles River Labs Appoints Glenn Coleman as New CFO - TipRanks
Charles River Laboratories International Inc (CRL) Q4 2025 Earni - GuruFocus
Charles River projects up to 9% EPS growth in 2026 as new CEO, acquisitions, and cost savings drive margin expansion - MSN
Glenn Coleman and Kerry Dailey to join Charles River Labs leadership - Investing.com Nigeria
Charles River Laboratories International (NYSE:CRL) Shares Gap DownWhat's Next? - MarketBeat
JPMorgan Cuts Charles River Laboratories International Price Target to $165 From $190, Maintains Neutral Rating - marketscreener.com
Charles River Lab Taps Veteran Atty For New CLO Post - Law360
Charles River Laboratories Q4 2025 earnings preview - MSN
C-suite changes continue at Charles River with new CFO, legal chief - The Business Journals
Charles River Laboratories International Q4 Earnings Call Highlights - MarketBeat
Laboratory Giant Charles River Reels-in Alcon Lawyer for New CLO Post - Law.com
New Charles River Leaders May Shape Valuation, Debt And Governance Outlook - simplywall.st
Charles River Laboratories International, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Charles River Laboratories Q4 Review: Approaching A Bottom (NYSE:CRL) - Seeking Alpha
CRL: 2026 outlook projects margin and EPS growth, with DSA recovery and cost savings offsetting early headwinds - TradingView
Charles River (CRL) Earnings Call Transcript - AOL.com
Charles River Laboratories Announces Executive Appointments - PharmiWeb.com
Charles River Laboratories International (NYSE:CRL) Issues Quarterly Earnings Results - MarketBeat
Charles River Laboratories International (NYSE:CRL) Issues FY 2026 Earnings Guidance - MarketBeat
Charles River Laboratories (CRL) Q4 revenue, adjusted earnings top expectations - AlphaStreet News
Here's What Key Metrics Tell Us About Charles River (CRL) Q4 Earnings - Yahoo Finance
Charles River Laboratories International, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 27, 2025 - marketscreener.com
CRL Stock Down Despite Q4 Earnings & Revenue Beat, Margins Rise - TradingView
Charles River Laboratories International, Inc. Announces Chief Financial Officer Changes, Effective April 6, 2026 - marketscreener.com
Charles River Laboratories (NYSE:CRL) Beats Q4 CY2025 Sales Expectations - Finviz
Charles River: Q4 Earnings Snapshot - KVUE
Charles River Laboratories (CRL) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance
Charles River forecasts upbeat 2026 profit on improved demand for drug development services - marketscreener.com
Charles River Q4 Adjusted Earnings, Revenue Decline; New CFO Named - marketscreener.com
CHARLES RIVER LABS INTL ($CRL) Releases Q4 2025 Earnings - Quiver Quantitative
Charles River Laboratories 8-K Filing Analysis - TradingView
Charles River Laboratories earnings beat by $0.04, revenue topped estimates - Investing.com Canada
CRL: Non-cash impairments drove GAAP losses, but 2026 guidance anticipates EPS growth - TradingView
Charles River Laboratories announces executive appointments - marketscreener.com
Charles River Labs beats Q4 expectations, provides cautious 2026 outlook - Investing.com
Charles River names Glenn Coleman as CFO, Kerry Dailey as CLO - StreetInsider
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance - Business Wire
Charles River Laboratories International, Inc. (NYSE: CRL) Q4 2025 earnings call transcript - MSN
Finanzdaten der Charles River Laboratories International Inc-Aktie (CRL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.95%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):